Calton & Associates Inc. raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 137.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 29,634 shares of the biopharmaceutical company's stock after purchasing an additional 17,151 shares during the period. Calton & Associates Inc.'s holdings in Pfizer were worth $751,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. bought a new stake in Pfizer during the 1st quarter valued at $28,000. Bernard Wealth Management Corp. bought a new stake in Pfizer during the 4th quarter valued at $30,000. Finally, Horizon Financial Services LLC acquired a new stake in shares of Pfizer in the first quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on PFE. BMO Capital Markets decreased their target price on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Leerink Partners dropped their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. TD Cowen dropped their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. Finally, Redburn Atlantic lowered their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average target price of $28.55.
Check Out Our Latest Stock Report on Pfizer
Pfizer Stock Performance
PFE traded up $0.38 during trading on Wednesday, hitting $25.52. The stock had a trading volume of 17,788,652 shares, compared to its average volume of 41,841,707. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm has a market capitalization of $145.06 billion, a P/E ratio of 18.49, a PEG ratio of 0.88 and a beta of 0.58. The company's 50-day moving average price is $24.07 and its 200 day moving average price is $24.71.
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.74%. Pfizer's dividend payout ratio is currently 124.64%.
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
